Literature DB >> 31235037

Responder of Gefitinib Plus Crizotinib in Osimertinib Failure EGFR-mutant NSCLC-Resistant With Newly Identified STRN-ALK by Next-Generation Sequencing.

Chunhua Zhou1, Liang Zeng1, Yongchang Zhang2, Nong Yang1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31235037     DOI： 10.1016/j.jtho.2019.02.014

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  6 in total

1.  ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non-small cell lung cancer.

Authors:  Helei Hou; Dantong Sun; Chuantao Zhang; Dong Liu; Xiaochun Zhang
Journal:  Thorac Cancer       Date:  2021-01-27       Impact factor: 3.500

Review 2.  Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.

Authors:  Mengnan Li; Zhou An; Qiusu Tang; Yutong Ma; Junrong Yan; Songan Chen; Yina Wang
Journal:  J Cell Mol Med       Date:  2021-09-19       Impact factor: 5.310

3.  Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports.

Authors:  Yue Zeng; Yuanqing Feng; Guihua Fu; Junlan Jiang; Xiaohan Liu; Yue Pan; Chunhong Hu; Xianling Liu; Fang Wu
Journal:  Front Pharmacol       Date:  2022-04-06       Impact factor: 5.988

4.  Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report.

Authors:  Hongbiao Wang; Sujuan Zhu; Zhifeng Li; Xiaofang Qi; Liwen Zhang; Leiyu Ke; Yingcheng Lin
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

5.  Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.

Authors:  Ying-Hsia Chu; Lori J Wirth; Alexander A Farahani; Vânia Nosé; William C Faquin; Dora Dias-Santagata; Peter M Sadow
Journal:  Mod Pathol       Date:  2020-07-31       Impact factor: 7.842

6.  STRN-ALK Fusion-Positive Case of Breast Cancer With Response to Alectinib.

Authors:  Andrew D Kelly; Tom Wiklund; Juha Kononen; James Creeden
Journal:  JCO Precis Oncol       Date:  2021-08-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.